Bicycle Therapeutics PLC (NASDAQ:BCYC)
| 19.90 Delayed Data As of Sep 26 |  -0.25 / -1.24%Today’s Change | 18.84 Today|||52-Week Range 33.49 | -32.77% Year-to-Date |
Institutional investors purchased a net $995.7 thousand shares of BCYC during the quarter ended March 2019. This may signal that the smart money is gaining interest in this company as the 73.15% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
| Other institutional | 56.02% |
| Mutual fund holders | 17.13% |
| Individual stakeholders | -- |
Largest Quarterly Institutional
Transactions
Latest Institutional Activity
| 6/30/2023 | FIRST LIGHT ASSET MANAGEMENT LLC Bought 1.0 Million shares of Bicycle Therapeutics PLC |
| 6/30/2023 | NOMURA SECURITIES CO., LTD. (PRI... Bought 400.0 Thousand shares of Bicycle Therapeutics PLC |
| 6/30/2023 | PARADIGM BIOCAPITAL ADVISORS LP Bought 168.6 Thousand shares of Bicycle Therapeutics PLC |
Top 10 Owners of Bicycle Therapeutics PLC
| Stockholder | Stake | Shares owned | Total value ($) | Shares bought / sold | Total change |
|---|---|---|---|---|---|
| Deep Track Capital LP | 7.68% | 2,819,045 | 61,286,038 | 0 | 0.00% |
| Ridgeback Capital Management LLC | 6.17% | 2,264,801 | 49,236,774 | +100,000 | +4.62% |
| Paradigm BioCapital Advisors LP | 5.41% | 1,985,430 | 43,163,248 | +168,649 | +9.28% |
| Jefferies LLC | 5.31% | 1,948,000 | 42,349,520 | 0 | 0.00% |
| First Light Asset Management LLC | 4.74% | 1,739,449 | 37,815,621 | +1,040,121 | +148.73% |
| Morgan Stanley & Co. LLC | 3.90% | 1,433,387 | 31,161,833 | -69,011 | -4.59% |
| Tybourne Capital Management (HK) ... | 3.49% | 1,281,820 | 27,866,767 | -127,011 | -9.02% |
| Janus Henderson Investors US LLC | 3.49% | 1,281,324 | 27,855,984 | -193,054 | -13.09% |
| Candriam Belgium SA | 3.47% | 1,273,261 | 27,680,694 | -29,950 | -2.30% |
| Sio Capital Management LLC | 2.64% | 968,671 | 21,058,908 | +1,324 | +0.14% |
Top 10 Mutual Funds Holding Bicycle Therapeutics PLC
| Mutual fund | Stake | Shares owned | Total value ($) | Shares bought / sold | Total change |
|---|---|---|---|---|---|
| Polar Capital Funds Plc - Biotech... | 2.58% | 948,000 | 20,609,520 | +198,000 | +26.40% |
| Belfius Equities - Cure | 2.09% | 767,934 | 16,694,885 | +25,000 | +3.37% |
| Candriam Equities L - Oncology Im... | 2.02% | 742,934 | 16,151,385 | +90,000 | +13.78% |
| Candriam Equities L - Biotechnolo... | 1.38% | 505,295 | 10,985,113 | +38,000 | +8.13% |
| Janus Henderson Global Life Scien... | 1.30% | 475,505 | 10,337,479 | -45,987 | -8.82% |
| BNP Paribas Funds - Health Care I... | 1.06% | 390,765 | 8,495,231 | 0 | 0.00% |
| Janus Henderson Capital Funds Plc... | 0.87% | 319,098 | 6,937,191 | -55,849 | -14.90% |
| Fidelity Select Port. - Biotechno... | 0.78% | 287,147 | 6,242,576 | 0 | 0.00% |
| AXA Framlington Biotech Fund | 0.78% | 286,644 | 6,231,641 | +5,929 | +2.11% |
| T Rowe Price Health Sciences Fund | 0.60% | 218,728 | 4,755,147 | -18,619 | -7.84% |